ArticleCancer research2013
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- PPARα activation alleviates lithocholic acid-induced liver injury by inhibiting pyroptosis.Liver research (Beijing, China) · 2026Article
- The future of Forkhead box O transcription factors.The Biochemical journal · 2026Review
- Activation of pregnane X receptor protects against cholestatic liver injury by inhibiting hepatocyte pyroptosis.Acta pharmacologica Sinica · 2025Article
- FOXO transcription factors as mediators of stress adaptation.Nature reviews. Molecular cell biology · 2024Review
- Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage.Clinical and translational science · 2023Article
- Interactions between the DNA Damage Response and the Telomere Complex in Carcinogenesis: A Hypothesis.Current issues in molecular biology · 2023Review
- FOXOs: masters of the equilibrium.The FEBS journal · 2022Review
- Autophagy induction promoted by mNature communications · 2022Article
- A coherent FOXO3-SNAI2 feed-forward loop in autophagy.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- The telomere complex and the origin of the cancer stem cell.Biomarker research · 2021Review
- Article
- The Role of Forkhead Box Family in Bone Metabolism and Diseases.Frontiers in pharmacology · 2021Review
- The Roles of FOXO1 in Periodontal Homeostasis and Disease.Journal of immunology research · 2021Review
- Phosphofructokinases Axis Controls Glucose-Dependent mTORC1 Activation Driven by E2F1.iScience · 2019Article
- Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas.Scientific reports · 2019Article
- Cross-talk among HMGA1 and FoxO1 in control of nuclear insulin signaling.Scientific reports · 2018Article
- Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells HarboringMolecular cancer therapeutics · 2018Article
- JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.Molecular cancer therapeutics · 2018Article
- E2F1 silencing inhibits migration and invasion of osteosarcoma cells via regulating DDR1 expression.International journal of oncology · 2017Article
- Trichostatin A attenuates oxidative stress-mediated myocardial injury through the FoxO3a signaling pathway.International journal of molecular medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The transcription factor E2F1 is a key regulator of proliferation and apoptosis but the molecular mechanisms that mediate these cell fate decisions remain unclear. Here, we identify FOXO transcription factors as E2F1 target genes that act in a feed-forward regulatory loop to reinforce gene induction of multiple apoptotic genes. We found that E2F1 forms a complex with FOXO1 and FOXO3. RNAi-mediated silencing of FOXO impaired E2F1 binding to the promoters of cooperative target genes. A FOXO3 mutant insensitive to inactivation by survival kinases rescued the inhibitory effect of growth factor signaling on E2F1-mediated transcription and apoptosis. The E2F1/FOXO axis is frequently blocked in cancer, as evidenced by the specific downregulation of the FOXO-dependent E2F1 transcriptional program in multiple cancer types and by the association of a reduced E2F1/FOXO transcriptional program with poor prognosis. HDAC and phosphoinositide 3-kinase (PI3K) inhibitors were identified as specific activators of E2F1/FOXO transcription, acting to enhance E2F1-induced apoptosis in a FOXO3-dependent manner. Notably, combining the histone deacetylase inhibitor vorinostat with a PI3K inhibitor led to enhanced FOXO-dependent apoptosis. Collectively, our results identify E2F1/FOXO cooperation as a regulatory mechanism that places E2F1 apoptotic activity under the control of survival signaling. Therapeutic reactivation of this tumor suppressive mechanism may offer a novel broad-acting therapy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.